Antibacterial drug treatment increases intestinal bile acid absorption via elevated levels of ileal apical sodium-dependent bile acid transporter but not organic solute transporter α protein

Biological & Pharmaceutical Bulletin
Masaaki MiyataKouichi Yoshinari

Abstract

Antibacterial drug treatment increases the bile acid pool size and hepatic bile acid concentration through the elevation of hepatic bile acid synthesis. However, the involvement of intestinal bile acid absorption in the increased bile acid pool size remains unclear. To determine whether intestinal bile acid absorption contributes to the increased bile acid pool in mice treated with antibacterial drugs, we evaluated the levels of bile acid transporter proteins and the capacity of intestinal bile acid absorption. Ileal apical sodium-dependent bile acid transporter (ASBT) mRNA and protein levels were significantly increased in ampicillin (ABPC)-treated mice, whereas organic solute transporter α (OSTα) mRNA levels, but not protein levels, significantly decreased in mice. Similar alterations in the expression levels of bile acid transporters were observed in mice treated with bacitracin/neomycin/streptomycin. The capacity for intestinal bile acid absorption was evaluated by an in situ loop method. Increased ileal absorption of taurochenodeoxycholic acid was observed in mice treated with ABPC. These results suggest that intestinal bile acid absorption is elevated in an ASBT-dependent manner in mice treated with antibacterial drugs.

References

Aug 1, 1984·The Journal of Clinical Investigation·N CarulliI Piccagli
Mar 15, 2003·The Journal of Biological Chemistry·Hirotaka KitadaYasushi Yamazoe
Jun 24, 2003·The Journal of Biological Chemistry·Paul A DawsonJohn S Parks
Nov 26, 2004·The Journal of Biological Chemistry·Paul A DawsonNazzareno Ballatori
Nov 5, 2005·American Journal of Physiology. Gastrointestinal and Liver Physiology·Jean-François LandrierGerd A Kullak-Ublick
Dec 1, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Nazzareno BallatoriNa Li
Apr 4, 2007·Pharmaceutical Research·Waddah A Alrefai, Ravinder K Gill
Feb 23, 2008·Proceedings of the National Academy of Sciences of the United States of America·Anuradha RaoPaul A Dawson
May 20, 2008·Cellular and Molecular Life Sciences : CMLS·A F Hofmann, L R Hagey
Jan 8, 2009·Physiological Reviews·Philippe LefebvreBart Staels
Jun 6, 2009·Journal of Lipid Research·Paul A DawsonAnuradha Rao
Sep 22, 2009·The Journal of Pharmacology and Experimental Therapeutics·Masaaki MiyataYasushi Yamazoe
Oct 5, 2010·The Journal of Pharmacology and Experimental Therapeutics·Masaaki MiyataYasushi Yamazoe
Jul 31, 2014·Pharmacological Reviews·Tiangang Li, John Y L Chiang

❮ Previous
Next ❯

Citations

Mar 16, 2017·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·A-Xi ShiXin-An Wu
May 18, 2018·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Cindy Yanfei LiJulia Yue Cui
Jul 23, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Felcy Pavithra SelwynCurtis D Klaassen
Apr 6, 2020·Pharmacology & Therapeutics·James J BeaudoinMelina M Malinen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.